<DOC>
	<DOCNO>NCT00634725</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . It yet know regimen chemotherapy without erlotinib and/or radiation therapy effective treating pancreatic cancer . PURPOSE : This randomized phase III trial study give gemcitabine together without capecitabine and/or radiation therapy see well work compare give gemcitabine together without erlotinib treat patient locally advanced pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Gemcitabine With Without Capecitabine and/or Radiation Therapy Gemcitabine With Without Erlotinib Treating Patients With Locally Advanced Pancreatic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess whether administrate chemoradiotherapy patient whose tumor control 4 month induction chemotherapy ( CT ) increase survival compare continuation CT patient unresectable , locally advanced adenocarcinoma pancreas . Secondary - To assess whether erlotinib hydrochloride combine gemcitabine hydrochloride administer maintenance treatment increase progression-free survival compare gemcitabine hydrochloride alone without maintenance treatment . - To evaluate response rate CT chemoradiotherapy ( CRT ) arm . - To evaluate tolerance erlotinib hydrochloride maintenance treatment end CT CRT . - To study predictive molecular factor ( i.e. , survivin , K-ras , EGFR , PTEN , AKT ) survival . OUTLINE : This multicenter study . Patients first randomization stratify accord center ECOG performance status ( 0-1 v 2 ) . Patients second randomization stratify accord center initial treatment arm ( I vs II ) . - First randomization : Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 . Following first evaluation , patient continue receive gemcitabine hydrochloride day 57 , 64 , 71 , 85 , 92 , 99 total 4 month . - Arm II : Patients receive gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 . Following first evaluation , patient continue receive gemcitabine hydrochloride day 57 , 64 , 71 , 85 , 92 , 99 . Patients also receive oral erlotinib hydrochloride daily 4 month . After completion treatment first randomization proceed second randomization . - Second randomization : Patients randomize 1 4 treatment arm . - Arm I : Patients continue gemcitabine hydrochloride arm I first randomization day 113 , 120 , 127 day 141 , 148 , 155 2 month absence disease progression . - Arm II : Patients continue gemcitabine hydrochloride arm II first randomization day 113 , 120 , 127 day 141 , 148 , 155 oral erlotinib hydrochloride daily 2 month follow erlotinib hydrochloride alone maintenance therapy absence disease progression . - Arm III : Patients receive oral capecitabine twice daily undergo radiotherapy begin day 127 , 5 day week , 6 week , absence disease progression . - Arm IV : Patients receive oral capecitabine twice daily undergo radiotherapy begin day 127 , 5 day week , 6 week . Beginning 15 day completion CRT , patient receive reintroduction oral erlotinib hydrochloride alone daily absence disease progression unacceptable toxicity . Tumor tissue analyze relationship biological marker resistance treatment . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas meeting follow criterion : De novo locally advanced disease Unresectable disease Stage III accord UICC classification No distant metastases No localized stage IAIIB metastatic stage IV disease accord UICC classification Not consider curative resection pluridisciplinary discussion PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Life expectancy ≥ 12 week Polynuclear neutrophil ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) For patient recent biliary drain whose bilirubin descending , value ≤ 3 time ULN acceptable Creatinine ≤ 2 mg/dL AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 5 time ULN Albumin ≥ 25 g/L Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion therapy Exclusion criterion : Diarrhea ≥ grade 2 and/or uncontrolled diarrhea Affiliated social security regime Unable follow instruction psychological , familial , geographical reason Allergic one ingredient erlotinib hydrochloride Cancer within past 5 year , except situ cancer neck uterus basal cell skin cancer Severe infection Ophthalmic disease ( i.e. , inflammation , keratopathy , infection ) Symptomatic coronary cardiac insufficiency , myocardial infarction , stroke within last 6 month Unable take oral treatment Gastrointestinal disorder could associate absorption disorder Untreated gastric duodenal ulcer PRIOR CONCURRENT THERAPY : No prior radiotherapy ( include abdominal radiotherapy ) chemotherapy reason No prior antiepidermal growth factorreceptor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
</DOC>